posted on 2018-11-07, 14:22authored byA. S. Pitek, H. Hu, S. Shukla, N. F. Steinmetz
Nanotechnology holds great promise
in cancer drug delivery, and of particular interest are theranostic
approaches in which drug delivery and imaging are integrated. In this
work, we studied and developed the plant virus tobacco mosaic virus
(TMV) as a platform nanotechnology for drug delivery and imaging.
Specifically, a serum albumin (SA)-coated TMV formulation was produced.
The SA coating fulfils two functions: SA provides a stealth coating
for enhanced biocompatibility; it also acts as a targeting ligand
enabling efficient tumor accumulation of SA-TMV versus TMV in mouse
models of breast and prostate cancer. We demonstrate drug delivery
of the chemotherapy doxorubicin (DOX); TMV-delivered DOX outperformed
free DOX, resulting in significant delayed tumor growth and increased
survival. Furthermore, we demonstrated the ability of SA-coated TMV
loaded with chelated Gd(DOTA) for magnetic resonance imaging detection
of tumors. In the future, we envision the application of such probes
as theranostic, where first imaging is performed to assess whether
the nanoparticles are effective at targeting a particular patient
tumor. If targeting is confirmed, the therapeutic would be added and
treatment can begin. The combination of imaging and therapy would
allow to monitor disease progression and therefore inform about the
effectiveness of the drug delivery approach.